SAGA Study

SAGA was a 24-month, double-masked, randomized, placebo-controlled trial to investigate the safety, pharmacokinetics, tolerability and efficacy in patients with geographic atrophy (GA) secondary to AMD.

The study enrolled 198 patients.

The primary efficacy endpoint was the growth rate of GA lesions from baseline to 24 months as assessed by Fundus Autofluorescence (FAF).

The first key secondary endpoint was the change in LLVA at 24 months.